Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Keros Therapeutics Inc’s stock clocked out at $16.42, down -2.32% from its previous closing price of $16.81. In other words, the price has decreased by -$2.32 from its previous closing price. On the day, 0.86 million shares were traded. KROS stock price reached its highest trading level at $17.25 during the session, while it also had its lowest trading level at $16.285.
Ratios:
To gain a deeper understanding of KROS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.03 and its Current Ratio is at 19.03. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on December 16, 2024, Reiterated its Outperform rating but revised its target price to $63 from $102 previously.
H.C. Wainwright reiterated its Buy rating for the stock on December 13, 2024, while the target price for the stock was revised from $100 to $47.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’24 when GORDON CARL L sold 250,000 shares for $44.01 per share. The transaction valued at 11,002,500 led to the insider holds 119,522 shares of the business.
ORBIMED ADVISORS LLC sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, OrbiMed Genesis Master Fund, L, who serves as the Shareholder of the company, bought 29,400 shares for $44.84 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 665131520 and an Enterprise Value of 153733648. For the stock, the TTM Price-to-Sale (P/S) ratio is 999.54 while its Price-to-Book (P/B) ratio in mrq is 1.21. Its current Enterprise Value per Revenue stands at 236.15 whereas that against EBITDA is -0.758.
Stock Price History:
Over the past 52 weeks, KROS has reached a high of $73.00, while it has fallen to a 52-week low of $15.67. The 50-Day Moving Average of the stock is -68.10%, while the 200-Day Moving Average is calculated to be -68.92%.
Shares Statistics:
It appears that KROS traded 828.61K shares on average per day over the past three months and 1809950 shares per day over the past ten days. A total of 39.26M shares are outstanding, with a floating share count of 30.96M. Insiders hold about 23.56% of the company’s shares, while institutions hold 79.02% stake in the company. Shares short for KROS as of 1734048000 were 3025140 with a Short Ratio of 3.65, compared to 1731628800 on 2224037. Therefore, it implies a Short% of Shares Outstanding of 3025140 and a Short% of Float of 10.17.
